Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
P/E ratio for Adicet Bio, Inc. (ACET)
P/E ratio as of 2023: -0.57
According to Adicet Bio, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.57. At the end of 2022 the company had a P/E ratio of -5.48.
P/E ratio history for Adicet Bio, Inc. from 2008 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.57 |
| 2022 | -5.48 |
| 2021 | -8.73 |
| 2020 | -2.80 |
| 2019 | -5.55 |
| 2018 | -193.36 |
| 2017 | -9.00 |
| 2016 | -318606.10 |
| 2015 | 9.60 |
| 2014 | 12.04 |
| 2013 | 12.04 |
| 2012 | 15.56 |
| 2011 | 28.71 |
| 2010 | 37.73 |
| 2009 | 28.21 |
| 2008 | 17.96 |